Harris Alex H S, Bowe Thomas, Hagedorn Hildi, Nevedal Andrea, Finlay Andrea K, Gidwani Risha, Rosen Craig, Kay Chad, Christopher Melissa
Center for Innovation to Implementation, Health Services Research and Development, VA Palo Alto Health Care System, Menlo Park, CA, USA.
Center for Chronic Disease Outcomes Research, Health Services Research and Development, VA Minneapolis Health Care System, Minneapolis, MN, USA.
Addict Sci Clin Pract. 2016 Sep 15;11(1):15. doi: 10.1186/s13722-016-0063-8.
Active consideration of effective medications to treat alcohol use disorder (AUD) is a consensus standard of care, yet knowledge and use of these medications are very low across diverse settings. This study evaluated the overall effectiveness a multifaceted academic detailing program to address this persistent quality problem in the US Veterans Health Administration (VHA), as well as the context and process factors that explained variation in effectiveness across sites.
An interrupted time series design, analyzed with mixed-effects segmented logistic regression, was used to evaluate changes in level and rate of change in the monthly percent of patients with a clinically documented AUD who received naltrexone, acamprosate, disulfiram, or topiramate. Using data from a 20 month post-implementation period, intervention sites (n = 37) were compared to their own 16 month pre-implementation performance and separately to the rest of VHA.
From immediately pre-intervention to the end of the observation period, the percent of patients in the intervention sites with AUD who received medication increased over 3.4 % in absolute terms and 68 % in relative terms (i.e., 4.9-8.3 %). This change was significant compared to the pre-implementation period in the intervention sites and secular trends in control sites. Sites with lower pre-implementation adoption, more person hours of detailing, but fewer people detailed, had larger immediate increases in medication receipt after implementation. The average number of detailing encounters per person was associated with steeper increases in slope over time.
This study found empirical support for a multifaceted quality improvement strategy aimed at increasing access to and utilization of pharmacotherapy for AUD. Future studies should focus on determining how to enhance the programs effects, especially in non-responsive locations.
积极考虑使用有效药物治疗酒精使用障碍(AUD)是护理的共识标准,但在不同环境中,这些药物的知晓率和使用率都非常低。本研究评估了一个多方面的学术推广项目在美国退伍军人健康管理局(VHA)解决这一持续存在的质量问题的总体效果,以及解释各地点效果差异的背景和过程因素。
采用中断时间序列设计,并通过混合效应分段逻辑回归进行分析,以评估接受纳曲酮、阿坎酸、双硫仑或托吡酯治疗的有临床记录的AUD患者每月百分比的水平和变化率的变化。利用实施后20个月的数据,将干预地点(n = 37)与其实施前16个月的表现进行比较,并分别与VHA的其他地区进行比较。
从干预前即刻到观察期结束,干预地点有AUD且接受药物治疗的患者百分比绝对值增加了3.4%以上,相对值增加了68%(即从4.9%增至8.3%)。与干预地点的实施前期以及对照地点的长期趋势相比,这一变化具有显著性。实施前采用率较低、推广时间较长但接受推广的人数较少的地点,实施后药物接受率的即刻增幅更大。每人平均推广接触次数与随时间推移斜率的更大增幅相关。
本研究为旨在增加AUD药物治疗可及性和利用率的多方面质量改进策略提供了实证支持。未来的研究应侧重于确定如何增强项目效果,尤其是在无反应的地区。